Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director | June 03, 2025 | June 04, 2025 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | President and COO | March 03, 2023 | March 08, 2023 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | October 26, 2023 | October 30, 2023 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | Director · President and CEO | July 10, 2017 | July 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 03, 2025 · Filed June 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,045 |
Reported balance
After 2025-06-03 transaction · row 1
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 60,000 · Balance 207,045 F1: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
Jazz Pharmaceuticals plc
Report date March 03, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,014 |
Ending reported balance
After 2023-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-03 · Grant · Acquired 13,456 · Balance 60,440 F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Row 2 · 2023-03-05 · Tax withholding · Disposed 5,426 · Balance 55,014 F2: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F2: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Protagonist Therapeutics, Inc
Report date October 26, 2023 · Filed October 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.21 · Expires 2033-10-26 | Direct | 45,000 |
Reported balance
After 2023-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-26 · Grant · Acquired 45,000 · Balance 45,000 F1: The options vest in 36 equal monthly installments following October 26, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 36 equal monthly installments following October 26, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Viracta Therapeutics, Inc.
Report date July 10, 2017 · Filed July 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.24 · Expires 2017-09-13 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-10 · Disposition to issuer · Disposed 4,306 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2019-08-31 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-10 · Disposition to issuer · Disposed 18,333 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.54 · Expires 2021-06-30 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-10 · Disposition to issuer · Disposed 118,435 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-10 · Disposition to issuer · Disposed 70,834 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.32 · Expires 2023-02-28 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-07-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2024-10-31 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-07-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2027-07-10 | Direct | 17,582 |
Reported balance
After 2017-07-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-07-10 · Grant · Acquired 17,582 · Balance 17,582 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F3: The option vests in monthly installments over three (3) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.30 · Expires 2024-02-28 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-07-10 · Disposition to issuer · Disposed 50,001 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2027-07-10 | Direct | 240,177 |
Reported balance
After 2017-07-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-07-10 · Grant · Acquired 240,177 · Balance 240,177 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F4: The option vests in monthly installments over two (2) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share.
F3: The option vests in monthly installments over three (3) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
F4: The option vests in monthly installments over two (2) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · derivative · entry 4 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 20,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 15,385 | $28.32 | $435,703.20 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · nonDerivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.30 to $28.38 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 4,615 | $28.39 | $131,019.85 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,385 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 8, 2022. The options subject to the net exercise were to expire on June 18, 2025. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0000899243-22-028147 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:19 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 39,866 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-034210 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,866 Underlying: Common Stock · 39,866 shares Expires 2032-05-31 F3 · price: Not applicable. F2 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:19 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 20,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034210 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,808 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.84 | $0.00 |
DisclosureSEC source: 0000899243-22-020697 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 31, 2022 over a one-year period. Read SEC document |
| March 05, 2022 Filed Mar 9, 2022 23:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,802 | $153.96 | $739,315.92 |
DisclosureSEC source: 0001765581-22-000030 · edgardoc.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,251 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 23:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 13,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000030 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,053 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,624 | $131.01 | $212,760.24 |
DisclosureSEC source: 0001765581-22-000004 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,546 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 147 and 62 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28 and November 30, 2021, respectively. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-21-035154 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 7,500 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 7,500 | $21.70 | $162,741.00 |
DisclosureSEC source: 0000899243-21-035154 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $21.63 to $21.79 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 7,500 | $6.55 | $49,125.00 |
DisclosureSEC source: 0000899243-21-035154 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:08 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 12,877 | Not disclosed Strike: $2.86 | Not disclosed |
DisclosureSEC source: 0001209191-21-049984 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,877 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: The option became exercisable in 12 equal monthly installments after the grant date. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:08 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 12,877 | $6.25 | $80,481.25 |
DisclosureSEC source: 0001209191-21-049984 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,354 F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:08 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 12,877 | $2.86 | $36,828.22 |
DisclosureSEC source: 0001209191-21-049984 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 00:08 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 35,295 | Not disclosed Strike: $5.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-037980 · doc4.xml · derivative · entry 4 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,295 Underlying: Common Stock · 35,295 shares Expires 2031-06-01 F4 · price: Not applicable. F5 · derivative.exercise_date: The option shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2022 Annual Meeting of Stockholders. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 00:08 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 17,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037980 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,354 F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-21-022135 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 7,500 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 7,500 | $21.48 | $161,085.00 |
DisclosureSEC source: 0000899243-21-022135 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $21.33 to $21.59 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 7,500 | $6.55 | $49,125.00 |
DisclosureSEC source: 0000899243-21-022135 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:08 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 15,961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037980 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. F4 · price: Not applicable. F3 · derivative.exercise_date: This RSU vested one year from the date of grant. F3 · derivative.expiration_date: This RSU vested one year from the date of grant. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:08 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 15,961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037980 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| May 26, 2021 Filed May 28, 2021 21:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0000899243-21-021135 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period. Read SEC document |
| May 18, 2021 Filed May 20, 2021 23:21 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-21-034627 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: The option became exercisable in 12 equal monthly installments after the grant date. Read SEC document |
| May 18, 2021 Filed May 20, 2021 23:21 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 5,000 | $5.75 | $28,735.00 |
DisclosureSEC source: 0001209191-21-034627 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,868 F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. F2 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.69 to $5.821 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| May 18, 2021 Filed May 20, 2021 23:21 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 5,000 | $2.90 | $14,500.00 |
DisclosureSEC source: 0001209191-21-034627 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-21-015311 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 7,500 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 7,500 | $24.14 | $181,036.50 |
DisclosureSEC source: 0000899243-21-015311 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.95 to $24.54 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 7,500 | $6.55 | $49,125.00 |
DisclosureSEC source: 0000899243-21-015311 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,718 | $164.75 | $612,540.50 |
DisclosureSEC source: 0001765581-21-000042 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,961 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000030 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,679 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-21-012100 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 10,000 shares Expires 2021-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: The option became exercisable in 12 equal monthly installments after the grant date. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 10,000 | $7.78 | $77,797.00 |
DisclosureSEC source: 0001209191-21-012100 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,868 F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. F2 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.68 to $7.941 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 10,000 | $2.90 | $29,000.00 |
DisclosureSEC source: 0001209191-21-012100 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 22:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-21-002704 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 22:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $28.74 | $143,686.50 |
DisclosureSEC source: 0000899243-21-002704 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.56 to $29.05 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 22:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $6.55 | $32,750.00 |
DisclosureSEC source: 0000899243-21-002704 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,607 | $160.40 | $257,762.80 |
DisclosureSEC source: 0001765581-21-000002 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,984 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 53 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:07 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-20-059454 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2021-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: The option became exercisable in 12 equal monthly installments after the grant date. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:07 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 10,000 | $6.25 | $62,505.00 |
DisclosureSEC source: 0001209191-20-059454 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,868 F2 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.26 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:07 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 10,000 | $2.90 | $29,000.00 |
DisclosureSEC source: 0001209191-20-059454 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was executed pursuant to a 10b5-1 plan. Read SEC document |
| October 19, 2020 Filed Oct 22, 2020 01:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-20-028931 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 19, 2020 Filed Oct 22, 2020 01:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $17.66 | $88,301.00 |
DisclosureSEC source: 0000899243-20-028931 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $17.51 to $17.96 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| October 19, 2020 Filed Oct 22, 2020 01:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $6.55 | $32,750.00 |
DisclosureSEC source: 0000899243-20-028931 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| July 17, 2020 Filed Jul 20, 2020 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-20-019714 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 17, 2020 Filed Jul 20, 2020 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $16.48 | $82,411.00 |
DisclosureSEC source: 0000899243-20-019714 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $16.37 to $16.62 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request. Read SEC document |
| July 17, 2020 Filed Jul 20, 2020 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $6.55 | $32,750.00 |
DisclosureSEC source: 0000899243-20-019714 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 23:58 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 13,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035413 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: This restricted stock unit vested one year from the date of grant. F2 · derivative.expiration_date: This restricted stock unit vested one year from the date of grant. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 23:58 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 13,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035413 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.